APA

Eiring A. M., Khorashad J. S., Anderson D. J., Yu F., Redwine H. M., Mason C. C., Reynolds K. R., Clair P. M., Gantz K. C., Zhang T. Y., Pomicter A. D., Kraft I. L., Bowler A. D., Johnson K., Partlin M. M., O'Hare T. & Deininger M. W. (20160413). β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. : Leukemia.

Chicago

Eiring A M, Khorashad J S, Anderson D J, Yu F, Redwine H M, Mason C C, Reynolds K R, Clair P M, Gantz K C, Zhang T Y, Pomicter A D, Kraft I L, Bowler A D, Johnson K, Partlin M Mac, O'Hare T and Deininger M W. 20160413. β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. : Leukemia.

Harvard

Eiring A. M., Khorashad J. S., Anderson D. J., Yu F., Redwine H. M., Mason C. C., Reynolds K. R., Clair P. M., Gantz K. C., Zhang T. Y., Pomicter A. D., Kraft I. L., Bowler A. D., Johnson K., Partlin M. M., O'Hare T. and Deininger M. W. (20160413). β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. : Leukemia.

MLA

Eiring A M, Khorashad J S, Anderson D J, Yu F, Redwine H M, Mason C C, Reynolds K R, Clair P M, Gantz K C, Zhang T Y, Pomicter A D, Kraft I L, Bowler A D, Johnson K, Partlin M Mac, O'Hare T and Deininger M W. β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. : Leukemia. 20160413.